TY - JOUR
T1 - Impact of ivabradine on health-related quality of life of patients with ischaemic chronic heart failure
AU - Sallam, Mansour
AU - Al-Saadi, Tariq
AU - Alshekaili, Latifa
AU - Al-Zakwani, Ibrahim
N1 - Publisher Copyright:
© 2016 Bentham Science Publishers.
PY - 2016
Y1 - 2016
N2 - Objective: Chronic heart failure (CHF) remains a major health problem, with high levels of morbidity and mortality and a low health-related quality of life (HRQoL). We assessed the impact on HRQoL of adding the If channel blocker, ivabradine, to a standard treatment regimen of patients with ischaemic CHF (I-CHF) and heart rate (HR) 70 beats/min (bpm). Methods: A randomized prospective study of 100 consecutive patients presenting with stable I-CHF, left ventricular ejection fraction (LVEF) <40% and a sinus HR ≥70 bpm. New York Heart Association (NYHA) class, overall summary score (OSS) and clinical summary score (CSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) were used to assess HRQoL. The patients were randomized into 2 groups: carvedilol only (group I (n=50)) and carvedilol + ivabradine (group II (n=50)). The patients were followed up for 12 weeks and their HRQoL scores were monitored and compared. Results: The overall mean age of the cohort was 63±10 years with 70% (n=70) males. HRQoL scores had significantly improved in group II after 12 weeks of follow-up. The net proportion of patients with a 5-point improvement in CSS was 30% higher in group II (p=0.002), whereas that for the OSS, it was 24% (p=0.001), when compared with group I. These improvements were accompanied by a significant HR reduction (69 vs 78 bpm; p=0.002). Conclusion: Adding ivabradine to the standard drug regimen, currently advocated by guidelines for CHF with a heart rate 70 bpm, resulted in a significant improvement in HRQoL.
AB - Objective: Chronic heart failure (CHF) remains a major health problem, with high levels of morbidity and mortality and a low health-related quality of life (HRQoL). We assessed the impact on HRQoL of adding the If channel blocker, ivabradine, to a standard treatment regimen of patients with ischaemic CHF (I-CHF) and heart rate (HR) 70 beats/min (bpm). Methods: A randomized prospective study of 100 consecutive patients presenting with stable I-CHF, left ventricular ejection fraction (LVEF) <40% and a sinus HR ≥70 bpm. New York Heart Association (NYHA) class, overall summary score (OSS) and clinical summary score (CSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) were used to assess HRQoL. The patients were randomized into 2 groups: carvedilol only (group I (n=50)) and carvedilol + ivabradine (group II (n=50)). The patients were followed up for 12 weeks and their HRQoL scores were monitored and compared. Results: The overall mean age of the cohort was 63±10 years with 70% (n=70) males. HRQoL scores had significantly improved in group II after 12 weeks of follow-up. The net proportion of patients with a 5-point improvement in CSS was 30% higher in group II (p=0.002), whereas that for the OSS, it was 24% (p=0.001), when compared with group I. These improvements were accompanied by a significant HR reduction (69 vs 78 bpm; p=0.002). Conclusion: Adding ivabradine to the standard drug regimen, currently advocated by guidelines for CHF with a heart rate 70 bpm, resulted in a significant improvement in HRQoL.
KW - Carvedilol
KW - Heart rate
KW - Ischaemic heart failure
KW - Ivabradine
KW - Kansas city cardiomyopathy questionnaire
KW - Oman
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85020282902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020282902&partnerID=8YFLogxK
U2 - 10.2174/1570161114666160505143003
DO - 10.2174/1570161114666160505143003
M3 - Article
C2 - 27145825
AN - SCOPUS:85020282902
SN - 1570-1611
VL - 14
SP - 481
EP - 486
JO - Current Vascular Pharmacology
JF - Current Vascular Pharmacology
IS - 5
ER -